Cap­si­da and Ab­b­Vie make $70M up­front deal for ge­net­ic med­i­cines in eye dis­eases

Ab­b­Vie is ex­pand­ing its part­ner­ship with gene ther­a­py de­vel­op­er Cap­si­da in a deal to de­vel­op ge­net­ic ther­a­pies for eye dis­eases.

The deal comes with a $70 mil­lion up­front pay­ment, as much as $595 mil­lion in mile­stone pay­ments, and pos­si­ble com­mer­cial pay­ments, ac­cord­ing to a state­ment from the com­pa­nies. Un­der the deal, they will iden­ti­fy and de­vel­op as many as three pro­grams.

The deal is an ex­pan­sion of Ab­b­Vie and Cap­si­da’s 2021 part­ner­ship, in which Ab­b­Vie made a $90 mil­lion up­front pay­ment and the com­pa­nies agreed to work on cen­tral ner­vous sys­tem dis­eases. And in Jan­u­ary, Cap­si­da an­nounced a part­ner­ship with Eli Lil­ly, tak­ing in $55 mil­lion in up­front pay­ments plus mile­stones to de­vel­op gene ther­a­pies for cen­tral ner­vous sys­tem dis­eases.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN